What is the 13F Pro Quality Score for RXRX?

13F Pro ranks RECURSION PHARMACEUTICALS, INC. (RXRX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View RXRX's current score at https://13fpro.ai/research/RXRX (free sign-up required for the full ranking).

Which hedge funds own the most RXRX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of RXRX include BlackRock,, ARK Investment Management, STATE STREET. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/RXRX as soon as new 13F filings post.

Where does 13F Pro source RXRX data?

All RECURSION PHARMACEUTICALS, INC. fundamentals and ownership data come directly from SEC EDGAR. RECURSION PHARMACEUTICALS, INC. files with the SEC under CIK 1601830. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is RXRX in?

RECURSION PHARMACEUTICALS, INC. (RXRX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is RXRX research updated on 13F Pro?

RXRX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

RECURSION PHARMACEUTICALS, INC.(RXRX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1601830 RXRX stock profile & AI dashboard →

13F Pro Quality Score

13.6/100

Rank #2,767 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

26.0/100

Profitability

2.0/100

Balance Sheet

4.0/100

Earnings Quality

30.0/100

Free Cash Flow

2.3/100

Institutional Flow

78.7/100

Revenue Scale

10.1/100

Dilution Risk

2.3/100

RXRX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for RECURSION PHARMACEUTICALS, INC. (RXRX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RXRX at 13.6/100 on a 32-signal composite quality model, placing it at rank #2,767 of 2,879 stocks — the bottom half of the AI-ranked universe. RXRX scores in the top quartile across institutional flow (78.7). Areas of concern include profitability (2.0) and free cash flow (2.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 2.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), RECURSION PHARMACEUTICALS, INC. reports quarterly revenue of $6.5M, net income of $-117.5M, free cash flow of $-81.4M. Top institutional holders of RXRX by reported 13-F value include BlackRock,, ARK Investment Management, STATE STREET, based on the most recent SEC filings. RXRX trades on the Nasdaq exchange and files with the SEC under CIK 1601830. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RXRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for RECURSION PHARMACEUTICALS, INC. directly from SEC EDGAR. RECURSION PHARMACEUTICALS, INC.'s 13F Pro composite quality score has ranged between 8 and 38 since 2022, currently 13.6 — a declining long-term trajectory across 52 quarterly and live scoring snapshots.

✦

Fun facts about RECURSION PHARMACEUTICALS, INC.

Quirks, history, and lore behind RXRX — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biotechnology company · listed on Nasdaq · headquartered in Utah · focused on drug discovery.
2
The Numbers
A clinical-stage company with minimal product revenue, spending heavily on R&D — its market cap has swung wildly but sits in the low billions, making it a mid-cap biotech bet.
3
The History
Founded around 2013, it was built on the premise that biology is a data problem — and that machines, not just scientists, should solve it.
4
The Secret
Its secret weapon is a massive automated laboratory that runs millions of experiments, feeding data into machine learning models to find drug candidates faster than any human team could.
5
The Lore
It struck a headline-grabbing partnership with NVIDIA to turbocharge its AI platform, putting it at the very center of the AI-meets-drug-discovery hype wave.
6
The Giveaway
The company's own name is a computing term, its ticker repeats its first two letters twice, and it wants to decode biology the way software debugs code — one loop at a time.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$6.5M

Net Income

Q1 2026

$-117.5M

Free Cash Flow

Q1 2026

$-81.4M

D/E Ratio

Q1 2026

0.02

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+26.9% YoY

$74.7MFY 2025

FY19 $2.3MFY20 $4.0MFY24 $58.8MFY25 $74.7M

Net Income

-39.1% YoY

$-644.8MFY 2025

FY19 $-61.9MFY20 $-87.0MFY24 $-463.7MFY25 $-644.8M

Operating Income

-35.3% YoY

$-648.1MFY 2025

FY19 $-62.4MFY20 $-84.6MFY24 $-479.0MFY25 $-648.1M

EPS (Diluted)

+14.8% YoY

$-1.44FY 2025

FY19 $-1.91FY20 $-2.66FY24 $-1.69FY25 $-1.44

Total Assets

+1.8% YoY

$1.47BFY 2025

FY19 —FY20 $298.6MFY24 $1.45BFY25 $1.47B

Total Debt

-32.0% YoY

$18.7MFY 2025

FY19 —FY20 —FY24 $27.4MFY25 $18.7M

Op. Cash Flow

-3.5% YoY

$-371.8MFY 2025

FY19 $-57.0MFY20 $-45.4MFY24 $-359.2MFY25 $-371.8M

Metric	FY 2025	FY 2024	FY 2020	FY 2019	FY 2018
Revenue	$74.7M +26.9%	$58.8M +1385.1%	$4.0M +70.8%	$2.3M	—
Net Income	$-644.8M -39.1%	$-463.7M -432.9%	$-87.0M -40.6%	$-61.9M	—
Operating Income	$-648.1M -35.3%	$-479.0M -466.1%	$-84.6M -35.5%	$-62.4M	—
EPS (Diluted)	$-1.44 +14.8%	$-1.69 +36.5%	$-2.66 -39.0%	$-1.91	—
Total Assets	$1.47B +1.8%	$1.45B +385.2%	$298.6M	—	—
Total Debt	$18.7M -32.0%	$27.4M	—	—	—
Operating Cash Flow	$-371.8M -3.5%	$-359.2M -691.1%	$-45.4M +20.4%	$-57.0M	—

AI Insight: RXRX Financial Trends

Recursion remains unprofitable with volatile revenue, but cash burn and debt are decelerating meaningfully.

• Operating cash outflow improved from $-132M (Q1 2025) to $-46M (Q4 2025), then widened to $-81M (Q1 2026).

• Total debt declined from $31M (Q2 2024) to $16M (Q1 2026); equity strengthened from $584M to $1,025M.

• Net loss narrowed from $-202M (Q1 2025) to $-108M (Q4 2025), though rebounded to $-118M (Q1 2026).

⚠ Revenue highly volatile (Q4 2025 spike to $36M collapsed to $6M in Q1 2026); underlying run-rate unclear.

⚠ Operating cash burn re-accelerated in Q1 2026 ($-81M) after Q4 2025 improvement; sustainability uncertain.

AI Insight: RXRX Ratio Trends

Losses narrowing sharply: ROA improved 16.5pp from Q1 2025 trough to Q4 2025, but company remains deeply unprofitable with negative ROIC of -49.4% in latest TTM.

• ROE swung from -86.7% in Q1 2025 to -38.2% in Q4 2025, a 48.5pp improvement over two quarters.

• ROA improved from -62.1% (Q1 2025) to -29.3% (Q4 2025), suggesting operating losses are contracting.

• ROIC remains deeply negative at -49.4% TTM; Q4 2025 showed -37.7%, still indicating value destruction.

⚠ Recent quarter (Q1 2026) shows deterioration: ROA slipped to -35.1% from Q4's -29.3%; momentum may be stalling.

⚠ Company has not achieved positive margins or returns; path to profitability and positive ROIC remains unproven.

Get alerted when RXRX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for RECURSION PHARMACEUTICALS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of RXRX

BlackRock, Inc.
$132.6M43,192,306 sh
ARK Investment Management LLC
$123.5M40,212,769 sh
STATE STREET CORP
$87.5M28,490,638 sh
BAILLIE GIFFORD & CO
$72.7M23,675,407 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$69.9M22,759,100 sh
VANGUARD CAPITAL MANAGEMENT LLC
$68.3M22,244,387 sh
SOFTBANK GROUP CORP.
$41.9M13,636,515 sh
GEODE CAPITAL MANAGEMENT, LLC
$37.7M12,275,084 sh
MIC Capital Management UK LLP
$29.6M9,644,032 sh
GOLDMAN SACHS GROUP INC
$18.6M6,065,661 sh

Fund	Value	Shares
BlackRock, Inc.	$132.6M	43,192,306
ARK Investment Management LLC	$123.5M	40,212,769
STATE STREET CORP	$87.5M	28,490,638
BAILLIE GIFFORD & CO	$72.7M	23,675,407
VANGUARD PORTFOLIO MANAGEMENT LLC	$69.9M	22,759,100
VANGUARD CAPITAL MANAGEMENT LLC	$68.3M	22,244,387
SOFTBANK GROUP CORP.	$41.9M	13,636,515
GEODE CAPITAL MANAGEMENT, LLC	$37.7M	12,275,084
MIC Capital Management UK LLP	$29.6M	9,644,032
GOLDMAN SACHS GROUP INC	$18.6M	6,065,661

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put RXRX on your watchlist

Track score changes the day RECURSION PHARMACEUTICALS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is RXRX a good stock to buy?

13F Pro's AI-powered analysis of RECURSION PHARMACEUTICALS, INC. (RXRX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RXRX are available on the RXRX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own RXRX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RXRX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of RECURSION PHARMACEUTICALS, INC.'s investment landscape.